KU
KURA.US Kura Oncology Inc
- Market cap
- USD 714M
- P/E
- -
- P/B
- 39.75x
- ROE
- -1,572.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KURA.US undervalued?
Graham numberThe Graham number of Kura Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kura Oncology Inc fundamental analysis
No fundamental analysis for Kura Oncology Inc yet.
Kura Oncology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibi…
Full company profileKura Oncology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kura Oncology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.9M | 67.5M | 82.6M |
| Gross Profit | -31.0K | -30.0K | -10.0K | - | -194K | -558K | -759K | -849K | 53.9M | 67.4M | 81.0M |
| Operating Income | -28.4M | -36.1M | -62.9M | -67.5M | -91.9M | -131M | -140M | -166M | -193M | -304M | -302M |
| EBITDA | -28.3M | -36.0M | -62.9M | -67.5M | -88.9M | -129M | -135M | -150M | -169M | -276M | -280M |
| Net Income | -27.6M | -35.4M | -60.4M | -63.1M | -89.6M | -130M | -136M | -153M | -174M | -279M | -283M |
| EPS | -1.47 | -1.52 | -1.72 | -1.51 | -1.69 | -1.97 | -2.03 | -2.08 | -2.02 | -3.18 | -3.15 |
| Balance Sheet | |||||||||||
| Total Assets | 69.8M | 95.9M | 182M | 242M | 647M | 534M | 456M | 449M | 760M | 738M | 566M |
| Total Liabilities | 12.9M | 16.0M | 21.4M | 23.2M | 36.3M | 27.4M | 36.0M | 51.7M | 347M | 564M | 549M |
| Shareholders' Equity | 56.9M | 79.9M | 161M | 219M | 611M | 507M | 420M | 397M | 414M | 174M | 18.0M |
| Cash & Short-term Investments | 67.8M | 93.1M | 179M | 237M | 633M | 518M | 438M | 424M | 727M | 667M | 492M |
| Total Debt | 7.32M | 7.10M | 7.50M | 7.75M | 15.0M | 6.88M | 14.0M | 17.2M | 16.6M | 20.5M | 25.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.3M | -28.4M | -48.7M | -54.8M | -69.8M | -105M | -110M | -125M | 134M | -64.1M | -270M |
| Capital Expenditure | 0.00 | 2.17M | 2.17M | 2.17M | 2.17M | 1.15M | 626K | 168K | 472K | 6.64M | 1.64M |
| Free Cash Flow | -25.3M | -28.4M | -48.7M | -54.8M | -72.0M | -106M | -111M | -125M | 134M | -70.7M | -272M |
| Ratios | |||||||||||
| ROE | -48.5% | -44.4% | -37.5% | -28.9% | -14.7% | -25.8% | -32.3% | -38.4% | -42.1% | -160.0% | -1,572.9% |
| ROA | -39.5% | -37.0% | -33.1% | -26.1% | -13.8% | -24.4% | -29.8% | -34.0% | -22.9% | -37.7% | -49.9% |
| Net Profit Margin | - | - | - | - | - | - | - | - | -322.9% | -412.9% | -341.9% |
| Debt to Equity | 0.13x | 0.09x | 0.05x | 0.04x | 0.02x | 0.01x | 0.03x | 0.04x | 0.04x | 0.12x | 1.44x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kura Oncology Inc dividends
Kura Oncology Inc has not paid dividends in the last 9 fiscal years.
Who owns Kura Oncology Inc
- Insiders 2.32%
- Institutions 97.68%
- Public & others 0.00%
- Shares outstanding 91.9M
- Free float 73.4M
Top funds holding KURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.80M | 3.05% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.73M | 2.97% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 2.14M | 2.33% | 0.00% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 1.61M | 1.75% | -10.00% | Sep 2026 |
| Fidelity Small Cap Index | 929K | 1.01% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 796K | 0.87% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 678K | 0.74% | -0.19% | Oct 2026 |
| abrdn Healthcare Investors | 664K | 0.72% | 0.00% | Oct 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 622K | 0.68% | -28.67% | Jan 2026 |
| BlackRock Advantage Small Cap Core Instl | 601K | 0.65% | +14.11% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 541K | 0.59% | +0.27% | Oct 2026 |
| Vanguard Russell 2000 ETF | 495K | 0.54% | +1.25% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 476K | 0.52% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 421K | 0.46% | -4.78% | Sep 2026 |
| Jupiter Merian Glb Eq Abs Rt I USD Acc | 413K | 0.45% | 0.00% | Jun 2026 |
| abrdn Life Sciences Investors | 407K | 0.44% | +28.07% | Oct 2026 |
| Sector Healthcare Value A USD | 341K | 0.37% | 0.00% | Sep 2026 |
| LVIP FranklinTempletonMltFctSMIDCapEqStd | 324K | 0.35% | +1,475.13% | Sep 2026 |
| Royce Micro-Cap Trust | 259K | 0.28% | +11.80% | Sep 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 248K | 0.27% | 0.00% | Oct 2026 |
Top institutions holding KURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 10.5M | 11.44% | +9.04% | Jun 2026 |
| Suvretta Capital Management, LLC | 8.58M | 9.33% | 0.00% | Jun 2026 |
| Bvf Inc | 8.45M | 9.19% | 0.00% | Jun 2026 |
| State Street Corp | 5.33M | 5.80% | +18.11% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.92M | 4.26% | +3.45% | Jun 2026 |
| Armistice Capital, LLC | 3.68M | 4.00% | -1.55% | Jun 2026 |
| AQR Capital Management LLC | 3.13M | 3.40% | +47.18% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.27M | 2.47% | +58.02% | Jun 2026 |
| Geode Capital Management, LLC | 2.23M | 2.43% | +9.62% | Jun 2026 |
| Alethea Capital Management, LLC | 2.17M | 2.36% | +41.75% | Jun 2026 |
| Prosight Management, LP | 2.02M | 2.20% | -39.76% | Jun 2026 |
| Renaissance Technologies Corp | 2.01M | 2.18% | +20.53% | Sep 2026 |
| Deep Track Capital, LP | 1.98M | 2.15% | -25.15% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.41M | 1.54% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.33M | 1.45% | +8.05% | Jun 2026 |
| NAN FUNG TRINITY (HK) Ltd | 1.17M | 1.28% | 0.00% | Sep 2026 |
| Qube Research & Technologies | 1.17M | 1.27% | -28.52% | Jun 2026 |
| Bank of America Corp | 1.16M | 1.26% | -5.63% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.16M | 1.26% | -0.32% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 996K | 1.08% | +24.42% | Jun 2026 |
Kura Oncology Inc company profile
- Company name
- Kura Oncology Inc
- Ticker
- KURA.US
- Exchange
- USA Stocks
- Listed since
- Sep 22, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 260
- Fiscal year end
- December
- Address
- 4930 Directors Place, San Diego, CA, United States, 92121
- Phone
- 858 500 8800
- Website
- kuraoncology.com
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Kura Oncology Inc management
10- Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President · born 1969
- Ms. Kathleen FordChief Operating Officer · born 1947
- Mr. Brian T. Powl M.B.A., M.S.Chief Commercial Officer · born 1974
- Ms. Jennifer FulkChief Financial Officer · born 1977
- Mr. Thomas DoyleSenior Vice President of Finance & Accounting · born 1971
- Dr. Francis J. Burrows Ph.D.Chief Scientific Officer · born 1962
- Mr. Greg MannSenior Vice President of Investor Relations & Corporate Affairs
- Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate Secretary · born 1971
- Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply Chain
- Dr. Mollie Leoni M.D.Chief Medical Officer · born 1978